Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a

Sam D. Sanderson, Marilyn L. Thoman, Kornelia Kis, Elizabeth L. Virts, Edgar B. Herrera, Stephanie Widmann, Homero Sepulveda, Joy A. Phillips

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The anaphylatoxin C5a is an especially potent mediator of both local and systemic inflammation. However, C5a also plays an essential role in mucosal host defense against bacterial, viral, and fungal infection. We have developed a response-selective agonist of human C5a, termed EP67, which retains the immunoenhancing activity of C5a at the expense of its inflammatory, anaphylagenic properties. EP67 insufflation results in the rapid induction of pulmonary cytokines and chemokines. This is followed by an influx of innate immune effector cells, including neutrophils, NK cells, and dendritic cells. EP67 exhibits both prophylactic and therapeutic protection when tested in a murine model of influenza A infection. Mice treated with EP67 within a twenty-four hour window of non-lethal infection were significantly protected from influenza-induced weight loss. Furthermore, EP67 delivered twenty-four hours after lethal infection completely blocked influenza-induced mortality (0% vs. 100% survival). Since protection based on innate immune induction is not restricted to any specific pathogen, EP67 may well prove equally efficacious against a wide variety of possible viral, bacterial, and fungal pathogens. Such a strategy could be used to stop the worldwide spread of emergent respiratory diseases, including but not limited to novel strains of influenza.

Original languageEnglish (US)
Article numbere40303
JournalPloS one
Volume7
Issue number7
DOIs
StatePublished - Jul 6 2012

Fingerprint

Pathogens
influenza
Human Influenza
agonists
Anaphylatoxins
Pulmonary diseases
Chemokines
infection
Infection
Cytokines
Insufflation
Mycoses
pathogens
natural killer cells
Virus Diseases
chemokines
dendritic cells
Bacterial Infections
Natural Killer Cells
Dendritic Cells

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Sanderson, S. D., Thoman, M. L., Kis, K., Virts, E. L., Herrera, E. B., Widmann, S., ... Phillips, J. A. (2012). Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a. PloS one, 7(7), [e40303]. https://doi.org/10.1371/journal.pone.0040303

Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a. / Sanderson, Sam D.; Thoman, Marilyn L.; Kis, Kornelia; Virts, Elizabeth L.; Herrera, Edgar B.; Widmann, Stephanie; Sepulveda, Homero; Phillips, Joy A.

In: PloS one, Vol. 7, No. 7, e40303, 06.07.2012.

Research output: Contribution to journalArticle

Sanderson, SD, Thoman, ML, Kis, K, Virts, EL, Herrera, EB, Widmann, S, Sepulveda, H & Phillips, JA 2012, 'Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a', PloS one, vol. 7, no. 7, e40303. https://doi.org/10.1371/journal.pone.0040303
Sanderson, Sam D. ; Thoman, Marilyn L. ; Kis, Kornelia ; Virts, Elizabeth L. ; Herrera, Edgar B. ; Widmann, Stephanie ; Sepulveda, Homero ; Phillips, Joy A. / Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a. In: PloS one. 2012 ; Vol. 7, No. 7.
@article{f06018b4031e44aa96b10d0b2e5f4e57,
title = "Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a",
abstract = "The anaphylatoxin C5a is an especially potent mediator of both local and systemic inflammation. However, C5a also plays an essential role in mucosal host defense against bacterial, viral, and fungal infection. We have developed a response-selective agonist of human C5a, termed EP67, which retains the immunoenhancing activity of C5a at the expense of its inflammatory, anaphylagenic properties. EP67 insufflation results in the rapid induction of pulmonary cytokines and chemokines. This is followed by an influx of innate immune effector cells, including neutrophils, NK cells, and dendritic cells. EP67 exhibits both prophylactic and therapeutic protection when tested in a murine model of influenza A infection. Mice treated with EP67 within a twenty-four hour window of non-lethal infection were significantly protected from influenza-induced weight loss. Furthermore, EP67 delivered twenty-four hours after lethal infection completely blocked influenza-induced mortality (0{\%} vs. 100{\%} survival). Since protection based on innate immune induction is not restricted to any specific pathogen, EP67 may well prove equally efficacious against a wide variety of possible viral, bacterial, and fungal pathogens. Such a strategy could be used to stop the worldwide spread of emergent respiratory diseases, including but not limited to novel strains of influenza.",
author = "Sanderson, {Sam D.} and Thoman, {Marilyn L.} and Kornelia Kis and Virts, {Elizabeth L.} and Herrera, {Edgar B.} and Stephanie Widmann and Homero Sepulveda and Phillips, {Joy A.}",
year = "2012",
month = "7",
day = "6",
doi = "10.1371/journal.pone.0040303",
language = "English (US)",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a

AU - Sanderson, Sam D.

AU - Thoman, Marilyn L.

AU - Kis, Kornelia

AU - Virts, Elizabeth L.

AU - Herrera, Edgar B.

AU - Widmann, Stephanie

AU - Sepulveda, Homero

AU - Phillips, Joy A.

PY - 2012/7/6

Y1 - 2012/7/6

N2 - The anaphylatoxin C5a is an especially potent mediator of both local and systemic inflammation. However, C5a also plays an essential role in mucosal host defense against bacterial, viral, and fungal infection. We have developed a response-selective agonist of human C5a, termed EP67, which retains the immunoenhancing activity of C5a at the expense of its inflammatory, anaphylagenic properties. EP67 insufflation results in the rapid induction of pulmonary cytokines and chemokines. This is followed by an influx of innate immune effector cells, including neutrophils, NK cells, and dendritic cells. EP67 exhibits both prophylactic and therapeutic protection when tested in a murine model of influenza A infection. Mice treated with EP67 within a twenty-four hour window of non-lethal infection were significantly protected from influenza-induced weight loss. Furthermore, EP67 delivered twenty-four hours after lethal infection completely blocked influenza-induced mortality (0% vs. 100% survival). Since protection based on innate immune induction is not restricted to any specific pathogen, EP67 may well prove equally efficacious against a wide variety of possible viral, bacterial, and fungal pathogens. Such a strategy could be used to stop the worldwide spread of emergent respiratory diseases, including but not limited to novel strains of influenza.

AB - The anaphylatoxin C5a is an especially potent mediator of both local and systemic inflammation. However, C5a also plays an essential role in mucosal host defense against bacterial, viral, and fungal infection. We have developed a response-selective agonist of human C5a, termed EP67, which retains the immunoenhancing activity of C5a at the expense of its inflammatory, anaphylagenic properties. EP67 insufflation results in the rapid induction of pulmonary cytokines and chemokines. This is followed by an influx of innate immune effector cells, including neutrophils, NK cells, and dendritic cells. EP67 exhibits both prophylactic and therapeutic protection when tested in a murine model of influenza A infection. Mice treated with EP67 within a twenty-four hour window of non-lethal infection were significantly protected from influenza-induced weight loss. Furthermore, EP67 delivered twenty-four hours after lethal infection completely blocked influenza-induced mortality (0% vs. 100% survival). Since protection based on innate immune induction is not restricted to any specific pathogen, EP67 may well prove equally efficacious against a wide variety of possible viral, bacterial, and fungal pathogens. Such a strategy could be used to stop the worldwide spread of emergent respiratory diseases, including but not limited to novel strains of influenza.

UR - http://www.scopus.com/inward/record.url?scp=84863649352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863649352&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0040303

DO - 10.1371/journal.pone.0040303

M3 - Article

C2 - 22792270

AN - SCOPUS:84863649352

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e40303

ER -